Skip to main content
Free research Free research Free target review with research home and workspace preview
Quick search ChEMBL 36
Loading Target Snapshot...
Querying ChEMBL database. This may take a few seconds.
Target Snapshot

CHEMBL239 Target Snapshot

Peroxisome proliferator-activated receptor alpha · SINGLE PROTEIN · Homo sapiens

Back to Search Search this target Browse approvals Evidence Card
5,004Compounds
1,100Assays
15Approved Drugs
5,793.0Activities
Free Research Context

Research home keeps recent targets

This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.

Research home Demo workspace
Navigation

Switch target

Move to another high-traffic target or paste a specific ChEMBL target ID.

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-13

Peroxisome proliferator-activated receptor alpha shows approved-linked disease relevance led by type 2 diabetes mellitus. 5 more disease programs remain visible in the same review block. 9 linked drugs keep the current disease frame grounded. Protein identity stays anchored to UniProt Q07869. Start with type 2 diabetes mellitus, then reuse UniProt Q07869 as the stable protein anchor across project notes and exports.

Review focus
Review-ready target frame

Start with type 2 diabetes mellitus, then reuse UniProt Q07869 as the stable protein anchor across project notes and exports.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-13 9 linked drugs
Open source guide
Disease program
type 2 diabetes mellitus

Peroxisome proliferator-activated receptor alpha shows approved-linked disease relevance led by type 2 diabetes mellitus. 5 more disease programs remain visible in the same review block. 9 linked drugs remain visible in the same block.

Start review with type 2 diabetes mellitus because it currently carries approved-linked support. Linked drugs include ALEGLITAZAR, ELAFIBRANOR, FENOFIBRATE, FENOFIBRIC ACID. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Disease source · ChEMBL drug mechanism + indication proxy
Approved-linked Open Targets-ready proxy 9 linked drugs
Open disease block
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Peroxisome proliferator-activated receptor alpha as ChEMBL target CHEMBL239, mapped to UniProt Q07869. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Peroxisome proliferator-activated receptor alpha
SINGLE PROTEIN · Homo sapiens
As of 2026-09-13
ChEMBL target ID
CHEMBL239
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
UniProt accession
Q07869
Peroxisome proliferator-activated receptor alpha
UniProt accession via ChEMBL component mapping As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Start here when your first question is whether Peroxisome proliferator-activated receptor alpha is the right protein anchor across sources, using UniProt Q07869 as the stable mapping.

Jump to Protein Context
Need disease fit before discussing compounds?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use this block first when you need to confirm why type 2 diabetes mellitus is currently framed as approved-linked support. It currently carries 9 linked drugs in the same disease frame.

Jump to Disease Context
Need a meeting-ready explanation of why this target matters?
Evidence Card
Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card
Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

Preferred NamePeroxisome proliferator-activated receptor alpha
Target TypeSINGLE PROTEIN
OrganismHomo sapiens
UniProtQ07869
ChEMBL ↗ UniProt ↗ NCBI Protein ↗

Next Actions

SearchRun a focused querySearch the database using this target name as the starting context. ApprovalsCheck approved moleculesSee which approved drugs connect back to this target and its surrounding signal space. FeedScan papers & updatesStay in the project thread while checking recent papers and platform updates.
UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein LabelPeroxisome proliferator-activated receptor alpha
UniProt AccessionQ07869
Component TypeProtein
Sequence Length468 aa

Peroxisome proliferator-activated receptor alpha

Source · UniProt accession via ChEMBL component mapping
UniProt Context ↗
Review Cue

How to read this target

Review this target as Peroxisome proliferator-activated receptor alpha, mapped to UniProt Q07869. Sequence length is 468 aa.

Mapped IDQ07869
Review namePeroxisome proliferator-activated receptor alpha
OrganismHomo sapiens
Disease Relevance

Disease Relevance & Evidence Level

Open Targets-ready disease context using the current target-indication evidence contract.

Approved-linked Open Targets-ready proxy

Peroxisome proliferator-activated receptor alpha shows approved-linked disease relevance led by type 2 diabetes mellitus. 5 more disease programs remain visible in the same review block.

Approved-linked Approved
type 2 diabetes mellitus
9 linked drugs · 9 direct · 9 efficacy
Linked drugALEGLITAZAR
Linked drugELAFIBRANOR
Linked drugFENOFIBRATE
Linked drugFENOFIBRIC ACID
Approved-linked Approved
cardiovascular disease
6 linked drugs · 6 direct · 6 efficacy
Linked drugCHOLINE FENOFIBRATE
Linked drugCIPROFIBRATE
Linked drugCLOFIBRATE
Linked drugFENOFIBRATE
Approved-linked Approved
Hypercholesterolemia
5 linked drugs · 5 direct · 5 efficacy
Linked drugCHOLINE FENOFIBRATE
Linked drugFENOFIBRATE
Linked drugFENOFIBRIC ACID
Linked drugK-877
Approved-linked Approved
coronary artery disease
4 linked drugs · 4 direct · 4 efficacy
Linked drugCHOLINE FENOFIBRATE
Linked drugCLOFIBRATE
Linked drugFENOFIBRATE
Linked drugGEMFIBROZIL
Approved-linked Approved
diabetes mellitus
4 linked drugs · 4 direct · 4 efficacy
Linked drugFENOFIBRATE
Linked drugIMIGLITAZAR
Linked drugMK-0767
Linked drugMURAGLITAZAR
Approved-linked Approved
Abdominal pain
1 linked drug · 1 direct · 1 efficacy
Linked drugGEMFIBROZIL
Source · ChEMBL drug mechanism + indication proxy
ChEMBL target record ↗
Review Cue

How to read disease relevance

Start review with type 2 diabetes mellitus because it currently carries approved-linked support. Linked drugs include ALEGLITAZAR, ELAFIBRANOR, FENOFIBRATE, FENOFIBRIC ACID. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Lead diseasetype 2 diabetes mellitus
Strongest levelApproved-linked
Block modeOpen Targets-ready proxy
Clinical Profile

Clinical Phase Distribution

15
Approved
14
Phase III
27
Phase II
2
Phase I
Assay Mix

Activity Type Distribution

IC501,303.0
KI209.0
EC504,242.0
KD39.0
Lead Set

Top Inhibitors (by pChEMBL)

ChEMBL IDpChEMBLTypeValue (nM)Phase
CHEMBL1813003 10.59 EC50 0.026 Preclinical
CHEMBL468160 10.52 EC50 0.03 Preclinical
CHEMBL21241 10.27 Ki 0.0541 Preclinical
CHEMBL481551 10.14 EC50 0.072 Preclinical
CHEMBL513145 10.05 EC50 0.089 Preclinical
CHEMBL1813008 10.0 EC50 0.1 Preclinical
CHEMBL3354987 9.8 EC50 0.16 Preclinical
CHEMBL467349 9.56 EC50 0.272 Preclinical
CHEMBL2088421 9.55 IC50 0.28 Preclinical
CHEMBL253310 9.52 EC50 0.3 Preclinical
Distribution

pChEMBL Value Distribution

637
5.0
775
5.5
757
6.0
561
6.5
493
7.0
302
7.5
227
8.0
74
8.5
37
9.0
4
9.5
pChEMBL
Approved Drugs

Approved Drugs

ELAFIBRANOR
CHEMBL3707395
Approved 2024
Properties Compare Identifier
PEMAFIBRATE
CHEMBL247951
Approved 2017
Properties Compare Identifier
ROSIGLITAZONE
CHEMBL121
Approved 1999
Properties Compare Identifier
FENOFIBRATE
CHEMBL672
Approved 1993
Properties Compare Identifier
CIPROFIBRATE
CHEMBL557555
Approved 1985
Properties Compare Identifier
BERBERINE
CHEMBL295124
Properties Compare Identifier
Assay Landscape

Assay Landscape

1,100
Total Assays
2,199
Tested Compounds
3
Assay Types
Binding — 835 assays, 2,199 compounds
BAO Format Assays Compounds Avg pChEMBL
cell-based format 511 1,033 6.2
single protein format 287 1,057 6.2
assay format 25 109 5.8
tissue-based format 12 0 —
Functional — 263 assays, 1,428 compounds
BAO Format Assays Compounds Avg pChEMBL
cell-based format 183 833 6.7
assay format 80 595 6.3
ADME — 2 assays, 14 compounds
BAO Format Assays Compounds Avg pChEMBL
cell-based format 2 14 5.1

Confidence Score Distribution

Source · ChEMBL 36 via Core Engine